What is it about?
As a result of the SARS-CoV-2 coronavirus disease (COVID-19), the entire world was come to a halt. This illness has been linked to neurological symptoms such as headache, dizziness, stroke, or seizures, in addition to atypical pneumonia and lung disease symptoms. It is still unclear whether SARS-CoV-2 has a direct or indirect link to seizures. In this study, we identified the most likely drug candidate for COVID-19 in people with epilepsy or COVID-19 patients experiencing seizures using a literature search and the Comparative Toxicogenomics Database. After searching for common molecular targets affecting SARS-CoV-2 and seizures, we discovered ivermectin, dexamethasone, anakinra, and tocilizumab for protection against both COVID-19 and seizures. Additionally, we identified valproic acid as the most likely pharmacotherapy for COVID-19 individuals who were suffering seizures among the antiseizure drugs.
Featured Image
Photo by David Veksler on Unsplash
Why is it important?
The findings will serve as the starting point for more research on the aetiology and therapeutic targeting techniques for this newly discovered infection that causes seizures or in individuals with epilepsy.
Perspectives
One of the most dangerous problems this world has faced in our lifetimes is the Covid-19 pandemic. The disease poses challenges to disease control and crisis management. Therefore, this article will contribute to the development of ideas for managing this disease and its associated problems, thereby improving health care.
Divya Goel
Jamia Hamdard
Read the Original
This page is a summary of: Pharmacotherapy for SARS-CoV-2 and Seizures for Drug Repurposing
Presumed on Mechanistic Targets, Current Molecular Pharmacologye, October 2022, Bentham Science Publishers,
DOI: 10.2174/1874467214666211013122528.
You can read the full text:
Contributors
The following have contributed to this page
